Please login to the form below

Not currently logged in
Email:
Password:

Solymbic

This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

Latest news

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the

  • Amgen's Humira biosimilars backed for EU approval Amgen's Humira biosimilars backed for EU approval

    Amgen's Humira biosimilars backed for EU approval. Amgevita and Solymbic prepare to challenge AbbVie’ s blockbuster. ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended for approval by the EMA's scientific advisory panel in

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics